1x10^6 mouse bone marrow cells were surface stained with 0.25 ug FITC Plus Anti-Mouse CD11b (M1/70) (FITC-65055, Clone:M1/70), and 0.25 ug APC Anti-Mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) (APC-65140, Clone: RB6-8C5), and 0.25 ug FITC Plus Rat IgG2b Isotype Control (LTF-2) (FITC-65211, Clone: LTF-2). Cells were not fixed.
1X10^6 C57BL/6 mouse bone marrow cells were surface co-stained with FITC Plus Anti-Mouse Ly-6G/Ly-6C (Gr-1) and 0.1 ug APC Anti-Mouse CD11b (APC-65055, Clone: M1/70) or 0.1 ug APC Rat IgG2b Isotype Control (LTF-2) (APC-65211, Clone: LTF-2). Cells were not fixed.
1X10^6 mouse bone marrow cells were surface stained with 0.2 ug Anti-Mouse CD11b (65055-1-Ig, Clone: M1/70) or 0.2 ug Isotype Control. Cells were not fixed.
Following cell separation, cell suspension was stained with FITC-CD45(F10-89-4) and PE-CD11b(ICRF44) antibodies. All viable cells are gated in the analysis. Left panel: CD11b+CD45+ cells before selection. Right panel: CD11b+CD45+ cells after depletion. Human CD11b magnetic beads are tested using PBMC from three donors.
Following cell separation, cell suspension was stained with FITC-CD45(F10-89-4) and PE-CD11b(ICRF44) antibodies. All viable cells are gated in the analysis. Left panel: CD11b+CD45+ cells before selection. Right panel: CD11b+CD45+ cells after depletion. Human CD11b magnetic beads are tested using PBMC from three donors.
1x10^6 mouse bone marrow cells were surface stained with 0.25 ug PerCP Anti-Mouse CD11b (M1/70) (CP-65055, Clone: M1/70) or unstained. Cells were then stained with 0.25 ug CoraLite® Plus 647 Anti-Mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) (CL647-65140, Clone: RB6-8C5). Cells were not fixed.
